SCHEMBL18017407

SCHEMBL18017407

COC(=O)c1ccc(C#CCC[C@@H](N)[C@H](C)c2cnc(Cl)c(C)c2)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.34
GAA P10253 2/20 0.34
LMNA P02545 1/20 0.34
MMP13 P45452 1/20 0.34
PTPN11 Q06124 1/20 0.33
DPP4 P27487 2/20 0.32
ALDH1A1 P00352 2/20 0.32
TDP1 Q9NUW8 2/20 0.32
KDM4E B2RXH2 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32
KMT2A Q03164 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ACACB O00763 1/20 0.32
POLB P06746 1/20 0.32
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9963002 0.85 CHRNB2 (0.40) MAPTGAALMNAMMP13PTPN11
SCHEMBL21278568 0.85 MMP13 (0.31) MAPTGAALMNAMMP13ALDH1A1
SCHEMBL18017384 0.82 NPC1 (0.39) MAPTPTPN11DPP4ALDH1A1TDP1
SCHEMBL18017397 0.81 ADORA2B (0.38) MAPTPTPN11DPP4ALDH1A1TDP1
SCHEMBL9963001 0.75 CHRNB2 (0.41) MAPTGAALMNAMMP13PTPN11
SCHEMBL9933447 0.73 CHRNB2 (0.35) MAPTGAAMMP13PTPN11DPP4
SCHEMBL21278205 0.70 NPC1 (0.34) PTPN11DPP4ALDH1A1TDP1KDM4E
SCHEMBL16619389 0.70 NPC1 (0.34) PTPN11DPP4ALDH1A1TDP1KDM4E
SCHEMBL21278410 0.68 ADORA2B (0.35) PTPN11DPP4
SCHEMBL3458276 0.65 PTPN11 (0.51) MAPTPTPN11ALDH1A1TDP1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 MAPT 1940/4885GAA 2424/4885LMNA 1887/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.